Immunitybio Inc
NASDAQ:IBRX
Immunitybio Inc
NASDAQ:IBRX
Price:
5.92
USD
4.96%
Market Closed
Market Cap:
$5.8B
Balance Sheet
Balance Sheet Decomposition
Immunitybio Inc
Immunitybio Inc
Balance Sheet Decomposition is not available for
Immunitybio Inc
Immunitybio Inc
Balance Sheet
Immunitybio Inc
Immunitybio Inc
Currency: USD
| Dec-2013 | Dec-2014 | Dec-2015 | Dec-2016 | Dec-2017 | Dec-2018 | Dec-2019 | Dec-2020 | Dec-2021 | Dec-2022 | Dec-2023 | Dec-2024 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | |||||||||||||
| Cash & Cash Equivalents |
0
|
59
|
176
|
8
|
24
|
17
|
16
|
35
|
181
|
105
|
265
|
143
|
|
| Cash Equivalents |
0
|
59
|
176
|
8
|
24
|
17
|
16
|
35
|
181
|
105
|
265
|
143
|
|
| Short-Term Investments |
0
|
0
|
118
|
191
|
104
|
58
|
36
|
61
|
136
|
3
|
1
|
6
|
|
| Total Receivables |
0
|
0
|
2
|
3
|
1
|
11
|
0
|
5
|
1
|
2
|
3
|
3
|
|
| Accounts Receivables |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
2
|
|
| Other Receivables |
0
|
0
|
2
|
0
|
0
|
0
|
0
|
5
|
0
|
0
|
0
|
0
|
|
| Inventory |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
8
|
|
| Other Current Assets |
0
|
0
|
2
|
4
|
3
|
3
|
4
|
11
|
16
|
32
|
24
|
24
|
|
| Total Current Assets |
1
|
59
|
298
|
205
|
133
|
89
|
56
|
112
|
334
|
141
|
294
|
185
|
|
| PP&E Net |
0
|
0
|
7
|
19
|
77
|
77
|
72
|
91
|
119
|
190
|
183
|
170
|
|
| PP&E Gross |
0
|
0
|
7
|
19
|
77
|
77
|
72
|
91
|
119
|
190
|
183
|
170
|
|
| Accumulated Depreciation |
0
|
0
|
0
|
1
|
4
|
12
|
19
|
42
|
53
|
69
|
84
|
100
|
|
| Intangible Assets |
1
|
0
|
7
|
5
|
3
|
1
|
0
|
2
|
1
|
20
|
17
|
15
|
|
| Goodwill |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
|
| Note Receivable |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
7
|
6
|
7
|
7
|
7
|
|
| Long-Term Investments |
0
|
0
|
55
|
88
|
38
|
14
|
11
|
9
|
1
|
1
|
1
|
0
|
|
| Other Long-Term Assets |
0
|
0
|
0
|
0
|
0
|
2
|
4
|
2
|
7
|
5
|
3
|
5
|
|
| Other Assets |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
|
| Total Assets |
2
N/A
|
60
+2 757%
|
367
+511%
|
318
-13%
|
250
-21%
|
182
-27%
|
143
-21%
|
221
+55%
|
469
+112%
|
362
-23%
|
504
+39%
|
383
-24%
|
|
| Liabilities | |||||||||||||
| Accounts Payable |
2
|
1
|
2
|
4
|
6
|
3
|
2
|
12
|
11
|
21
|
9
|
7
|
|
| Accrued Liabilities |
1
|
0
|
3
|
6
|
11
|
21
|
9
|
39
|
54
|
43
|
46
|
47
|
|
| Short-Term Debt |
2
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
299
|
432
|
0
|
0
|
|
| Current Portion of Long-Term Debt |
0
|
0
|
0
|
0
|
0
|
1
|
1
|
16
|
0
|
1
|
1
|
1
|
|
| Other Current Liabilities |
0
|
0
|
2
|
3
|
4
|
2
|
1
|
2
|
4
|
4
|
1
|
0
|
|
| Total Current Liabilities |
4
|
2
|
6
|
13
|
21
|
27
|
12
|
68
|
369
|
501
|
58
|
55
|
|
| Long-Term Debt |
0
|
0
|
0
|
2
|
2
|
6
|
0
|
254
|
306
|
241
|
837
|
746
|
|
| Deferred Income Tax |
0
|
0
|
1
|
1
|
1
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Minority Interest |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
2
|
3
|
1
|
1
|
|
| Other Liabilities |
1
|
1
|
4
|
9
|
9
|
3
|
11
|
17
|
37
|
70
|
195
|
70
|
|
| Total Liabilities |
5
N/A
|
2
-52%
|
11
+354%
|
24
+121%
|
32
+31%
|
36
+14%
|
22
-38%
|
341
+1 423%
|
711
+108%
|
810
+14%
|
1 091
+35%
|
872
-20%
|
|
| Equity | |||||||||||||
| Common Stock |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Retained Earnings |
7
|
14
|
250
|
387
|
499
|
595
|
662
|
1 615
|
1 962
|
2 379
|
2 962
|
3 375
|
|
| Additional Paid In Capital |
4
|
71
|
607
|
681
|
718
|
741
|
783
|
1 495
|
1 720
|
1 931
|
2 375
|
2 885
|
|
| Other Equity |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
|
| Total Equity |
3
N/A
|
58
N/A
|
356
+518%
|
293
-18%
|
219
-25%
|
146
-33%
|
121
-17%
|
120
N/A
|
242
-102%
|
447
-85%
|
587
-31%
|
489
+17%
|
|
| Total Liabilities & Equity |
2
N/A
|
60
+2 757%
|
367
+511%
|
318
-13%
|
250
-21%
|
182
-27%
|
143
-21%
|
221
+55%
|
469
+112%
|
362
-23%
|
504
+39%
|
383
-24%
|
|
| Shares Outstanding | |||||||||||||
| Common Shares Outstanding |
77
|
61
|
81
|
82
|
79
|
79
|
99
|
382
|
398
|
421
|
671
|
853
|
|
Switch to:
Switch to:
See Also
Discover More
